207 related articles for article (PubMed ID: 35435231)
1. Intraglandular Off-the-Shelf Allogeneic Mesenchymal Stem Cell Treatment in Patients with Radiation-Induced Xerostomia: A Safety Study (MESRIX-II).
Lynggaard CD; Grønhøj C; Christensen R; Fischer-Nielsen A; Melchiors J; Specht L; Andersen E; Mortensen J; Oturai P; Barfod GH; Haastrup EK; Møller-Hansen M; Haack-Sørensen M; Ekblond A; Kastrup J; Jensen SB; von Buchwald C
Stem Cells Transl Med; 2022 May; 11(5):478-489. PubMed ID: 35435231
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal Stem/Stromal Cell Therapy for Radiation-Induced Xerostomia in Previous Head and Neck Cancer Patients: A Phase II Randomized, Placebo-Controlled Trial.
Jakobsen KK; Carlander AF; Todsen T; Melchiors J; Paaske N; Østergaard Madsen AK; Kloch Bendtsen S; Mordhorst C; Stampe H; Kastrup J; Ekblond A; Haack-Sørensen M; Farhadi M; Maare C; Friborg J; Lynggaard CD; Werner Hauge A; Christensen R; Grønhøj C; von Buchwald C
Clin Cancer Res; 2024 May; 30(10):2078-2084. PubMed ID: 38441659
[TBL] [Abstract][Full Text] [Related]
3. Long-term Safety of Treatment with Autologous Mesenchymal Stem Cells in Patients with Radiation-Induced Xerostomia: Primary Results of the MESRIX Phase I/II Randomized Trial.
Lynggaard CD; Grønhøj C; Jensen SB; Christensen R; Specht L; Andersen E; Andersen TT; Ciochon UM; Rathje GS; Hansen AE; Stampe H; Fischer-Nielsen A; von Buchwald C
Clin Cancer Res; 2022 Jul; 28(13):2890-2897. PubMed ID: 35486613
[TBL] [Abstract][Full Text] [Related]
4. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): A pilot, first-in-human study of interferon gamma-stimulated marrow mesenchymal stromal cells for treatment of radiation-induced xerostomia.
Blitzer GC; Glazer T; Burr A; Gustafson S; Ganz O; Meyers R; McDowell KA; Nickel KP; Mattison RJ; Weiss M; Chappell R; Rogus-Pulia NM; Galipeau J; Kimple RJ
Cytotherapy; 2023 Nov; 25(11):1139-1144. PubMed ID: 37589639
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of mesenchymal stem/stromal cell for radiation-induced hyposalivation and xerostomia in previous head and neck cancer patients (MESRIX-III): a study protocol for a single-centre, double-blinded, randomised, placebo-controlled, phase II study.
Jakobsen KK; Carlander AF; Grønhøj C; Todsen T; Melchiors J; Paaske N; Madsen AKØ; Kastrup J; Ekblond A; Haack-Sørensen M; Farhadi M; Maare C; Friborg J; Lynggard CD; von Buchwald C
Trials; 2023 Sep; 24(1):567. PubMed ID: 37658468
[TBL] [Abstract][Full Text] [Related]
6. Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction (MARSH): Study protocol for a phase 1 dose-escalation trial of patients with xerostomia after radiation therapy for head and neck cancer: MARSH: Marrow-Derived Autologous Stromal Cells for the Restoration of Salivary Hypofunction.
Blitzer GC; Rogus-Pulia NM; Mattison RJ; Varghese T; Ganz O; Chappell R; Galipeau J; McDowell KA; Meyers RO; Glazer TA; Kimple RJ
Cytotherapy; 2022 May; 24(5):534-543. PubMed ID: 35183442
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Mesenchymal Stem Cells for Radiation-Induced Xerostomia: A Randomized, Placebo-Controlled Phase 1/2 Trial (MESRIX).
Grønhøj C; Jensen DH; Vester-Glowinski P; Jensen SB; Bardow A; Oliveri RS; Fog LM; Specht L; Thomsen C; Darkner S; Jensen M; Müller V; Kiss K; Agander T; Andersen E; Fischer-Nielsen A; von Buchwald C
Int J Radiat Oncol Biol Phys; 2018 Jul; 101(3):581-592. PubMed ID: 29678523
[TBL] [Abstract][Full Text] [Related]
8. Functionality of bone marrow mesenchymal stromal cells derived from head and neck cancer patients - A FDA-IND enabling study regarding MSC-based treatments for radiation-induced xerostomia.
Blitzer GC; Paz C; Glassey A; Ganz OR; Giri J; Pennati A; Meyers RO; Bates AM; Nickel KP; Weiss M; Morris ZS; Mattison RJ; McDowell KA; Croxford E; Chappell RJ; Glazer TA; Rogus-Pulia NM; Galipeau J; Kimple RJ
Radiother Oncol; 2024 Mar; 192():110093. PubMed ID: 38224919
[TBL] [Abstract][Full Text] [Related]
9. Post-radiation xerostomia therapy with allogeneic mesenchymal stromal stem cells in patients with head and neck cancer: study protocol for phase I clinical trial.
Strojan P; Plavc G; Kokalj M; Mitrovic G; Blatnik O; Lezaic L; Socan A; Bavec A; Tesic N; Hartman K; Svajger U
Radiol Oncol; 2023 Dec; 57(4):538-549. PubMed ID: 38038413
[TBL] [Abstract][Full Text] [Related]
10. First-in-man mesenchymal stem cells for radiation-induced xerostomia (MESRIX): study protocol for a randomized controlled trial.
Grønhøj C; Jensen DH; Glovinski PV; Jensen SB; Bardow A; Oliveri RS; Specht L; Thomsen C; Darkner S; Kiss K; Fischer-Nielsen A; von Buchwald C
Trials; 2017 Mar; 18(1):108. PubMed ID: 28270226
[TBL] [Abstract][Full Text] [Related]
11. Does radiation dose to the salivary glands and oral cavity predict patient-rated xerostomia and sticky saliva in head and neck cancer patients treated with curative radiotherapy?
Jellema AP; Doornaert P; Slotman BJ; Leemans CR; Langendijk JA
Radiother Oncol; 2005 Nov; 77(2):164-71. PubMed ID: 16256229
[TBL] [Abstract][Full Text] [Related]
12. Does hyperbaric oxygen treatment have the potential to increase salivary flow rate and reduce xerostomia in previously irradiated head and neck cancer patients? A pilot study.
Forner L; Hyldegaard O; von Brockdorff AS; Specht L; Andersen E; Jansen EC; Hillerup S; Nauntofte B; Jensen SB
Oral Oncol; 2011 Jun; 47(6):546-51. PubMed ID: 21493124
[TBL] [Abstract][Full Text] [Related]
13. Phase 1 clinical study of cell therapy with effective-mononuclear cells (E-MNC) for radiogenic xerostomia (first-in-human study) (FIH study on E-MNC therapy for radiogenic xerostomia).
Sumita Y; Iwamoto N; Seki M; Yoshida T; Honma R; Iwatake M; Ohba S; Takashi I; Hotokezaka Y; Harada H; Kuroshima S; Nagai K; Asahara T; Atsushi Kawakam I; Asahina I
Medicine (Baltimore); 2020 Jun; 99(26):e20788. PubMed ID: 32590759
[TBL] [Abstract][Full Text] [Related]
14. Long-Term Outcome Following Treatment With Allogeneic Mesenchymal Stem/Stromal Cells for Radiation-Induced Hyposalivation and Xerostomia.
Jakobsen KK; Lynggaard CD; Paaske N; Carlander AF; Kastrup J; Hauge AW; Christensen R; Grønhøj C; Buchwald CV
Stem Cells Transl Med; 2024 Apr; ():. PubMed ID: 38578768
[TBL] [Abstract][Full Text] [Related]
15. Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: the role of dosimetric and clinical factors.
Beetz I; Schilstra C; Burlage FR; Koken PW; Doornaert P; Bijl HP; Chouvalova O; Leemans CR; de Bock GH; Christianen ME; van der Laan BF; Vissink A; Steenbakkers RJ; Langendijk JA
Radiother Oncol; 2012 Oct; 105(1):86-93. PubMed ID: 21632133
[TBL] [Abstract][Full Text] [Related]
16. Objective and subjective assessment of xerostomia in patients of locally advanced head-and-neck cancers treated by intensity-modulated radiotherapy.
Lal P; Nautiyal V; Verma M; Yadav R; Maria Das KJ; Kumar S
J Cancer Res Ther; 2018; 14(6):1196-1201. PubMed ID: 30488829
[TBL] [Abstract][Full Text] [Related]
17. Relationship between patient and physician-rated xerostomia and dose distribution to the oral cavity and salivary glands for head and neck cancer patients after radiotherapy.
Kaae JK; Johnsen L; Hansen CR; Kristensen MH; Brink C; Eriksen JG
Acta Oncol; 2019 Oct; 58(10):1366-1372. PubMed ID: 31241381
[No Abstract] [Full Text] [Related]
18. A phase II study to assess the efficacy of amifostine for submandibular/sublingual salivary sparing during the treatment of head and neck cancer with intensity modulated radiation therapy for parotid salivary sparing.
Rosenthal DI; Chambers MS; Weber RS; Eisbruch A
Semin Oncol; 2004 Dec; 31(6 Suppl 18):25-8. PubMed ID: 15726519
[TBL] [Abstract][Full Text] [Related]
19. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three-dimensional radiation therapy: initial results.
Chao KS; Deasy JO; Markman J; Haynie J; Perez CA; Purdy JA; Low DA
Int J Radiat Oncol Biol Phys; 2001 Mar; 49(4):907-16. PubMed ID: 11240231
[TBL] [Abstract][Full Text] [Related]
20. Clinical evaluation of a commercially available oral moisturizer in relieving signs and symptoms of xerostomia in postirradiation head and neck cancer patients and patients with Sjögren's syndrome.
Rhodus NL; Bereuter J
J Otolaryngol; 2000 Feb; 29(1):28-34. PubMed ID: 10709169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
